Medical Xpress October 11, 2024
As immunotherapy makes breakthrough progress in the treatment of small cell lung cancer (SCLC), predicting treatment outcomes has become a focal point in clinical practice. Immunotherapy combined with chemotherapy has been approved as first-line therapy for small cell lung cancer due to its survival benefit in randomized controlled trials. However, predicting its efficacy remains a challenge in the absence of currently available biomarkers.
A study titled “Neural network models based on clinical characteristics for predicting immunotherapy efficacy in small cell lung cancer” and published in Malignancy Spectrum, utilized deep-learning techniques to develop a novel predictive model, providing clinicians with a powerful decision-making aid.
The research team retrospectively analyzed data from 140 SCLC patients who underwent immunotherapy, dividing them into a...
Today's Sponsors
Today's Sponsor